Parvin Asset Management LLC Buys Shares of 19,245 Bristol Myers Squibb Company $BMY

Key Points

• Parvin Asset Management purchased 19,245 Bristol Myers Squibb shares worth approximately $1.1 million in the second quarter. Institutional investors collectively own 76.41% of the company.
• Bristol Myers Squibb reported quarterly EPS of $2.04, beating estimates of $1.60, while revenue rose 5.7% year over year to $12.97 billion. The company guided for fiscal 2026 EPS of $6.75–$7.00.
• The company pays a quarterly dividend of $0.63, equivalent to a 3.7% annual yield. Analysts give the stock a consensus “Moderate Buy” rating with an average price target of $66.06.

Parvin Asset Management LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 19,245 shares of the biopharmaceutical company's stock, valued at approximately $1,109,000.

A number of other hedge funds have also bought and sold shares of the business. Proficio Capital Partners LLC purchased a new position in shares of Bristol Myers Squibb during the second quarter worth about $360,000. Stonebridge Capital Management Inc. purchased a new stake in Bristol Myers Squibb in the second quarter valued at approximately $779,000. Pure Financial Advisors LLC bought a new stake in Bristol Myers Squibb during the second quarter valued at approximately $1,295,000. Transamerica Financial Advisors LLC purchased a new position in Bristol Myers Squibb in the 2nd quarter worth approximately $1,521,000. Finally, Corient Private Wealth LP bought a new position in shares of Bristol Myers Squibb in the 2nd quarter worth $30,484,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $67.68 on Thursday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64. The stock has a market capitalization of $138.25 billion, a P/E ratio of 14.91, a P/E/G ratio of 0.18 and a beta of 0.22. The company's 50-day moving average is $61.25 and its 200 day moving average is $59.60. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company's quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.7%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 55.51%.

Insider Activity at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business's stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.05% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Citigroup reissued a "neutral" rating and issued a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. Piper Sandler began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued an "overweight" rating for the company. Bank of America reduced their price objective on Bristol Myers Squibb from $67.00 to $66.00 and set a "buy" rating on the stock in a research report on Friday, July 10th. Argus upgraded Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 target price for the company in a research report on Wednesday, August 5th. Finally, TD Cowen initiated coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a "buy" rating on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $66.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source